Strategists conclude the IPO wave doesn’t necessarily portend a dangerous market bubble – yet ...

Jersey Mike's goes public July 30 on the NYSE under ticker JMKE. Here are three brokers where retail investors can register ...

The startup is the first gene editing company to price an IPO in more than two years, though it banked far less than most ...

Jersey Mike's is preparing for a major IPO with plans to expand globally. Its prospectus highlights growth potential and the ...

Beijing's AI leaders are rushing toward the public markets, using IPOs to fund an escalating arms race against U.S. frontier ...

IPO, if you’re on the friends and family list and can get the initial IPO price, then … maybe. Otherwise, avoid the hype.

Attovia Therapeutics is pursuing a U.S. IPO to fund its immune-mediated disease drug pipeline, led by ATTO-1310. Learn more ...

These companies are nearing trillion-dollar valuations. However, only one is actually living up to the hype at the moment.

While U.S. IPO issuance is on track for a record-breaking year, Goldman Sachs views the surge as a normalization of market activity.

Axiom Biosciences is thinking outside of the box, betting on a public debut in Hong Kong to raise capital and grow into a ...

Scribe Therapeutics is a Phase 1 clinical-stage biopharma developing in vivo CRISPR gene editing for disease prevention, ...